MA55593A - Cycles pyridine contenant des dérivés servant d'inhibiteurs de malt1 - Google Patents
Cycles pyridine contenant des dérivés servant d'inhibiteurs de malt1Info
- Publication number
- MA55593A MA55593A MA055593A MA55593A MA55593A MA 55593 A MA55593 A MA 55593A MA 055593 A MA055593 A MA 055593A MA 55593 A MA55593 A MA 55593A MA 55593 A MA55593 A MA 55593A
- Authority
- MA
- Morocco
- Prior art keywords
- containing derivatives
- cycles containing
- derivatives serving
- malt1 inhibitors
- pyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962832608P | 2019-04-11 | 2019-04-11 | |
| EP19178959 | 2019-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55593A true MA55593A (fr) | 2022-02-16 |
Family
ID=70224393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055593A MA55593A (fr) | 2019-04-11 | 2020-04-10 | Cycles pyridine contenant des dérivés servant d'inhibiteurs de malt1 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12404260B2 (fr) |
| EP (1) | EP3953345B1 (fr) |
| JP (1) | JP7554768B2 (fr) |
| KR (1) | KR20210151880A (fr) |
| CN (1) | CN113677674B (fr) |
| AU (1) | AU2020272156A1 (fr) |
| BR (1) | BR112021019799A2 (fr) |
| ES (1) | ES2949871T3 (fr) |
| MA (1) | MA55593A (fr) |
| MX (1) | MX2021012417A (fr) |
| WO (1) | WO2020208222A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| EP3953345B1 (fr) | 2019-04-11 | 2023-04-05 | Janssen Pharmaceutica NV | Dérivés de pyridines comme inhibiteurs de malt1 |
| US20230414629A1 (en) * | 2020-11-12 | 2023-12-28 | Monopteros Therapeutics, Inc. | Materials and methods of treating cancer |
| AU2022425324A1 (en) | 2021-12-30 | 2024-05-30 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Tricyclic derivative inhibitor, preparation method therefor, and application thereof |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6339099B1 (en) | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
| DK173431B1 (da) | 1998-03-20 | 2000-10-23 | Gea Farmaceutisk Fabrik As | Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs |
| FR2795726A1 (fr) | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
| GB9925127D0 (en) | 1999-10-22 | 1999-12-22 | Pharmacia & Upjohn Spa | Oral formulations for anti-tumor compounds |
| DE60235114D1 (de) | 2001-11-01 | 2010-03-04 | Icagen Inc | Pyrazolamide zur anwendung in der behandlung von schmerz |
| CA2522994C (fr) | 2003-04-30 | 2012-09-25 | Agensys, Inc. | Acides nucleiques et proteines correspondantes appelees 109p1d4 utiles dans le traitement et la detection du cancer |
| AU2004236240C1 (en) | 2003-05-01 | 2010-11-04 | Bristol-Myers Squibb Company | Aryl-substituted pyrazole compounds useful as kinase inhibitors |
| US20090156582A1 (en) | 2005-02-09 | 2009-06-18 | Tetsuya Tsukamoto | Pyrazole Compound |
| RU2008141761A (ru) | 2006-03-22 | 2010-04-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | ИНГИБИТОРЫ с-МЕТ ПРОТЕИНКИНАЗЫ |
| CA2657660A1 (fr) | 2006-07-12 | 2008-01-17 | Merck & Co., Inc. | Pyrazoles substitues servant d'antagonistes des recepteurs de la ghreline |
| US8389544B2 (en) | 2007-01-17 | 2013-03-05 | The Hong Kong University Of Science And Technology | Isoquinolone compounds as subtype-selective agonists for melatonin receptors MT1 and MT2 |
| BRPI0721430A2 (pt) | 2007-03-09 | 2013-01-08 | High Point Pharmaceuticals Llc | amidas indol e benzimidazol como inibidoras de hidroxiesteràide deidrogenase |
| US8309523B2 (en) | 2007-11-21 | 2012-11-13 | Vib Vzw | Inhibitors of MALT1 proteolytic activity and uses thereof |
| WO2009146555A1 (fr) * | 2008-06-04 | 2009-12-10 | Ambrilia Biopharma Inc. | Inhibiteurs de l'intégrase du vih, issus de la pyridoxine |
| EA020661B1 (ru) | 2008-09-24 | 2014-12-30 | Басф Се | Пиразольные соединения для борьбы с беспозвоночными вредителями |
| WO2010039039A1 (fr) | 2008-10-03 | 2010-04-08 | Clavis Pharma Asa | Formulations orales de dérivés de gemcitabine |
| KR101061599B1 (ko) | 2008-12-05 | 2011-09-02 | 한국과학기술연구원 | 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물 |
| DE102009003954A1 (de) | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Pyridazinonderivate |
| US8252821B2 (en) | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| WO2011036885A1 (fr) | 2009-09-25 | 2011-03-31 | 武田薬品工業株式会社 | Composé hétérocyclique |
| US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
| CA3007787C (fr) | 2010-06-03 | 2020-03-10 | Pharmacyclics Llc | Utilisation d'inhibiteurs de la tyrosine kinase de bruton (btk) |
| CN102947270B (zh) | 2010-06-22 | 2015-04-08 | 巴斯夫欧洲公司 | 制备4-羟基吡啶的方法 |
| JP2013530199A (ja) | 2010-07-06 | 2013-07-25 | ノバルティス アーゲー | キナーゼ阻害剤として有用な環状エーテル化合物 |
| TW201236685A (en) | 2010-11-11 | 2012-09-16 | Daiichi Sankyo Co Ltd | New pyrazole amide derivatives |
| KR20150020228A (ko) | 2012-05-31 | 2015-02-25 | 에프. 호프만-라 로슈 아게 | 아미노퀴나졸린 및 피리도피리미딘 유도체 |
| EP2890695A2 (fr) | 2012-08-29 | 2015-07-08 | Respivert Limited | Inhibiteurs de kinase |
| EP2916656B1 (fr) | 2012-11-09 | 2017-10-25 | Cornell University | Inhibiteurs de malt1 à petites molécules |
| WO2014086478A1 (fr) | 2012-12-03 | 2014-06-12 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Inhibiteurs de la protéase malt1 |
| HK1216300A1 (zh) | 2013-01-10 | 2016-11-04 | Grünenthal GmbH | 作为crac通道抑制剂的基於吡唑基的甲醯胺i |
| KR20170007311A (ko) * | 2014-05-28 | 2017-01-18 | 노파르티스 아게 | 신규 피라졸로 피리미딘 유도체 및 malt1 억제제로서의 그의 용도 |
| WO2015192081A1 (fr) | 2014-06-13 | 2015-12-17 | Byrd, John C. | Biomarqueur permettant de prédire la réponse d'une llc à un traitement avec un inhibiteur de la btk |
| WO2016005994A2 (fr) | 2014-07-06 | 2016-01-14 | Gattefosse India Pvt. Ltd. | Composition pharmaceutique comprenant une dispersion solide de médicaments de classe ii bcs avec gelucires |
| JP2017523207A (ja) | 2014-08-08 | 2017-08-17 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ阻害薬の組み合わせ及びそれらの使用 |
| MX381233B (es) | 2014-09-10 | 2025-03-12 | Glaxosmithkline Ip Dev Ltd | Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret). |
| US10105349B2 (en) | 2014-12-06 | 2018-10-23 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2016209688A1 (fr) | 2015-06-24 | 2016-12-29 | University Of Florida Research Foundation, Incorporated | Compositions destinées au traitement du cancer, et leurs utilisations |
| EP4086259A1 (fr) * | 2015-11-06 | 2022-11-09 | Incyte Corporation | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma |
| MX2018005390A (es) * | 2015-11-13 | 2018-08-16 | Novartis Ag | Nuevos derivados de pirazolo pirimidina. |
| JO3794B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
| CN107021963A (zh) | 2016-01-29 | 2017-08-08 | 北京诺诚健华医药科技有限公司 | 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用 |
| WO2017151786A1 (fr) | 2016-03-01 | 2017-09-08 | University Of Maryland, Baltimore | Inhibiteurs de la voie de signalisation wnt pour le traitement de maladies |
| KR20190033607A (ko) * | 2016-07-29 | 2019-03-29 | 루핀 리미티드 | Malt1 저해제로서의 치환 티아졸로-피리딘 화합물 |
| WO2018103060A1 (fr) | 2016-12-09 | 2018-06-14 | Janssen Pharmaceutica Nv | Inhibiteurs de tyrosine kinase de bruton et leurs procédés d'utilisation |
| JOP20190141A1 (ar) | 2016-12-21 | 2019-06-12 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي |
| JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
| ES2862922T7 (en) | 2016-12-21 | 2025-02-26 | Mereo Biopharma 3 Ltd | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| CA3046578A1 (fr) | 2016-12-21 | 2018-06-28 | Acerta Pharma B.V. | Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| JOP20190148A1 (ar) | 2016-12-21 | 2019-06-18 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية |
| EP3576744A1 (fr) | 2017-02-01 | 2019-12-11 | Medivir Aktiebolag | Applications thérapeutiques d'inhibiteurs de malt1 |
| WO2018165385A1 (fr) | 2017-03-08 | 2018-09-13 | Cornell University | Inhibiteurs de malt1 et leurs utilisations |
| WO2018226150A1 (fr) | 2017-06-05 | 2018-12-13 | Medivir Aktiebolag | Pyrazolopyrimidine utilisés en tant qu'inhibiteurs de malt-1 |
| CN111770759A (zh) | 2017-12-28 | 2020-10-13 | 通用医疗公司 | 靶向cbm信号体复合物诱导调节性t细胞使肿瘤微环境发炎 |
| CN111801245B (zh) | 2018-02-23 | 2024-04-30 | 工业设备运营公司 | 产生磁场的设备以及对交通工具动态充电的感应式充电系统的初级装置 |
| MX2020013699A (es) | 2018-06-18 | 2021-05-12 | Janssen Pharmaceutica Nv | Derivados de pirazol como inhibidores de malt1. |
| CN112585128B (zh) * | 2018-06-18 | 2023-02-21 | 詹森药业有限公司 | 作为malt1抑制剂的吡唑衍生物 |
| US12269813B2 (en) | 2019-02-22 | 2025-04-08 | Janssen Pharmaceutica Nv | Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazole-4-carboxamide monohydrate |
| MX2021010144A (es) | 2019-02-22 | 2021-09-14 | Janssen Pharmaceutica Nv | Formulaciones farmaceuticas. |
| EP3953345B1 (fr) | 2019-04-11 | 2023-04-05 | Janssen Pharmaceutica NV | Dérivés de pyridines comme inhibiteurs de malt1 |
| US20210155990A1 (en) | 2019-11-22 | 2021-05-27 | Janssen Pharmaceutica Nv | Nf-kb regulated gene expression assay for assessing efficacy of malt1 inhibitors |
| IL293146A (en) | 2019-11-22 | 2022-07-01 | Janssen Pharmaceutica Nv | Methods for evaluating the efficacy of malt1 inhibitors using the nf-kb knockdown assay |
| WO2021138298A1 (fr) | 2019-12-30 | 2021-07-08 | Rheos Medicines, Inc. | Modulateurs de malt1 et leurs utilisations |
| KR20230054394A (ko) | 2020-08-21 | 2023-04-24 | 얀센 파마슈티카 엔.브이. | 비정질 형태의 malt1 억제제 및 이의 제형 |
| EP4199911A1 (fr) | 2020-08-21 | 2023-06-28 | JANSSEN Pharmaceutica NV | Formulations pharmaceutiques comprenant un inhibiteur de malt1 et un mélange de polyéthylèneglycol et d'un acide gras |
| WO2022185097A1 (fr) | 2021-03-03 | 2022-09-09 | Janssen Pharmaceutica Nv | Méthode de traitement d'une affection à l'aide d'une dose thérapeutiquement efficace de l'inhibiteur de malt1 jnj-67856633 (1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluorométhyl)-n-(2-(trifluorométhyl)pyridin-4-yl)-1 h-pyrazole-4-carboxamide) |
| CA3212015A1 (fr) | 2021-03-03 | 2022-09-09 | Janssen Pharmaceutica Nv | Polytherapie utilisant un inhibiteur de malt1 et un inhibiteur de btk |
-
2020
- 2020-04-10 EP EP20717667.8A patent/EP3953345B1/fr active Active
- 2020-04-10 ES ES20717667T patent/ES2949871T3/es active Active
- 2020-04-10 KR KR1020217036345A patent/KR20210151880A/ko not_active Withdrawn
- 2020-04-10 MA MA055593A patent/MA55593A/fr unknown
- 2020-04-10 US US17/602,885 patent/US12404260B2/en active Active
- 2020-04-10 WO PCT/EP2020/060307 patent/WO2020208222A1/fr not_active Ceased
- 2020-04-10 AU AU2020272156A patent/AU2020272156A1/en not_active Abandoned
- 2020-04-10 BR BR112021019799A patent/BR112021019799A2/pt not_active Application Discontinuation
- 2020-04-10 JP JP2021559711A patent/JP7554768B2/ja active Active
- 2020-04-10 MX MX2021012417A patent/MX2021012417A/es unknown
- 2020-04-10 CN CN202080028070.1A patent/CN113677674B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021012417A (es) | 2021-11-12 |
| WO2020208222A1 (fr) | 2020-10-15 |
| US20220162187A1 (en) | 2022-05-26 |
| CN113677674B (zh) | 2024-08-23 |
| JP7554768B2 (ja) | 2024-09-20 |
| BR112021019799A2 (pt) | 2021-12-07 |
| US12404260B2 (en) | 2025-09-02 |
| AU2020272156A1 (en) | 2021-10-14 |
| EP3953345A1 (fr) | 2022-02-16 |
| CA3131856A1 (fr) | 2020-10-15 |
| KR20210151880A (ko) | 2021-12-14 |
| EP3953345B1 (fr) | 2023-04-05 |
| ES2949871T3 (es) | 2023-10-03 |
| JP2022528919A (ja) | 2022-06-16 |
| CN113677674A (zh) | 2021-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55593A (fr) | Cycles pyridine contenant des dérivés servant d'inhibiteurs de malt1 | |
| CY1122821T1 (el) | Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2 | |
| MA56021A (fr) | Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3 | |
| PH12020550786A1 (en) | Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors | |
| AR106237A2 (es) | Inhibidores heterocíclicos de la aspartil proteasa, sus sales farmacéuticamente aceptables | |
| MA47125A (fr) | Dérivés de pyrazole en tant qu'inhibiteurs de malt1 | |
| MA49013A (fr) | Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 | |
| SA518391307B1 (ar) | مركبات ومشتقات سبيرو [ إندول -3، 2- بيروليدين h3] أون جديدة على هيئة مثبطات الدقيقة المزدوجة للفأر(1h)2 بي2-53 | |
| MX2013007104A (es) | Derivados de biciclo[3,2,1]octilamida y sus usos. | |
| CR10359A (es) | Derivados de dihidropirazolopirimidinona | |
| GEAP202015169A (en) | Tyrosine amide derivatives as rho-kinase inhibitors | |
| BR112015018509A2 (pt) | compostos de imidazo piridina | |
| MA41901A (fr) | Compositions contenant de l'ibrutinib | |
| UY31940A (es) | Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones | |
| EP3733673A4 (fr) | Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase | |
| MA51429A (fr) | Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase | |
| EP3941525A4 (fr) | Dérivés de benzodiazépine en tant qu'inhibiteurs de rsv | |
| PE20180412A1 (es) | Compuestos inhibidores de la senalizacion de la via de notch | |
| AR097894A1 (es) | Inhibidores terapéuticos de cdk8 o uso de los mismos | |
| EP3449001A4 (fr) | Inhibition de l'arnmi mir-22 par apt-110 | |
| CY1116168T1 (el) | Συγκρυσταλλοι και αλατα αναστολεων toy ccr3 | |
| EP3946288A4 (fr) | Dérivés de 5-cyclopropyl-1h-pyrazol-3-yl-amine substitués utilisés en tant qu'inhibiteurs sélectifs de cdk12/13 | |
| EP4043450A4 (fr) | Dérivés 2h-benzopyrane utilisables en tant qu'inhibiteurs de crac | |
| MA53643A (fr) | Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6 | |
| EA201892264A1 (ru) | Производные тетрагидроизохинолина |